INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
Corporate insider
GC

Gibson Christopher

Director, Chief Executive OfficerCIK 0001856369

EDGAR filingsOpen in network
Disclosed transactions33
Buys / sells0 / 9
Max Insider Score21
Connections2with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
0
GC
Gibson ChristopherDirector
RXRXRECURSION PHARMACEUTICALS, INC.
Derivative conversion · 10b5-1 plan
C—
40.0K sh
Jun 5, 2026Jun 5, 2026
traded Jun 5, 2026
+0dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    PACIFIC BIOSCIENCES OF CALIFORNIA, INC.Director · Apr 10, 2026
  • Insider ofevidence
    RECURSION PHARMACEUTICALS, INC.Director, Chief Executive Officer · Nov 6, 2025
0
GC
Gibson ChristopherDirector
RXRXRECURSION PHARMACEUTICALS, INC.
Derivative conversion · 10b5-1 plan
C
—
40.0K sh
Jun 5, 2026
Jun 5, 2026
traded Jun 5, 2026
+0d
SEC FORM 4

Evidence

16
GC
Gibson ChristopherDirector
RXRXRECURSION PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$145K
40.0K sh
Jun 5, 2026Jun 5, 2026
traded Jun 5, 2026
+0dSEC FORM 4

Evidence

0
GC
Gibson ChristopherDirector
RXRXRECURSION PHARMACEUTICALS, INC.
Derivative conversion · 10b5-1 plan
C—
40.0K sh
Apr 22, 2026Apr 24, 2026
traded Apr 22, 2026
+2dSEC FORM 4

Evidence

6
GC
Gibson ChristopherDirector
RXRXRECURSION PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$144K
40.0K sh
Apr 22, 2026Apr 24, 2026
traded Apr 22, 2026
+2dSEC FORM 4

Evidence

0
GC
Gibson ChristopherDirector
RXRXRECURSION PHARMACEUTICALS, INC.
Derivative conversion · 10b5-1 plan
C—
40.0K sh
Apr 22, 2026Apr 24, 2026
traded Apr 22, 2026
+2dSEC FORM 4

Evidence

9
GC
Gibson ChristopherDirector
PACBPACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Grant or award
A—
77.8K sh
Apr 8, 2026Apr 10, 2026
traded Apr 8, 2026
+2dSEC FORM 4

Evidence

21
GC
Gibson ChristopherDirector
PACBPACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Grant or award
A—
57.5K sh
Apr 8, 2026Apr 10, 2026
traded Apr 8, 2026
+2dSEC FORM 4

Evidence

6
GC
Gibson ChristopherDirector
RXRXRECURSION PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$124K
40.0K sh
Apr 7, 2026Apr 8, 2026
traded Apr 7, 2026
+1dSEC FORM 4

Evidence

0
GC
Gibson ChristopherDirector
RXRXRECURSION PHARMACEUTICALS, INC.
Derivative conversion · 10b5-1 plan
C—
40.0K sh
Apr 7, 2026Apr 8, 2026
traded Apr 7, 2026
+1dSEC FORM 4

Evidence

0
GC
Gibson ChristopherDirector
RXRXRECURSION PHARMACEUTICALS, INC.
Derivative conversion · 10b5-1 plan
C—
40.0K sh
Apr 7, 2026Apr 8, 2026
traded Apr 7, 2026
+1dSEC FORM 4

Evidence

9
GC
Gibson ChristopherDirector
RXRXRECURSION PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$179K
40.0K sh
Jan 20, 2026Jan 22, 2026
traded Jan 20, 2026
+2dSEC FORM 4

Evidence

0
GC
Gibson ChristopherDirector
RXRXRECURSION PHARMACEUTICALS, INC.
Derivative conversion · 10b5-1 plan
C—
40.0K sh
Jan 20, 2026Jan 22, 2026
traded Jan 20, 2026
+2dSEC FORM 4

Evidence

0
GC
Gibson ChristopherDirector
RXRXRECURSION PHARMACEUTICALS, INC.
Derivative conversion · 10b5-1 plan
C—
40.0K sh
Jan 20, 2026Jan 22, 2026
traded Jan 20, 2026
+2dSEC FORM 4

Evidence

0
GC
Gibson ChristopherDirector
RXRXRECURSION PHARMACEUTICALS, INC.
Gift · 10b5-1 plan
G—
20.0K sh
Jan 5, 2026Jan 7, 2026
traded Jan 5, 2026
+2dSEC FORM 4

Evidence

0
GC
Gibson ChristopherDirector
RXRXRECURSION PHARMACEUTICALS, INC.
Derivative conversion · 10b5-1 plan
C—
60.0K sh
Jan 5, 2026Jan 7, 2026
traded Jan 5, 2026
+2dSEC FORM 4

Evidence

14
GC
Gibson ChristopherDirector
RXRXRECURSION PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$170K
40.0K sh
Jan 5, 2026Jan 7, 2026
traded Jan 5, 2026
+2dSEC FORM 4

Evidence

0
GC
Gibson ChristopherDirector
RXRXRECURSION PHARMACEUTICALS, INC.
Derivative conversion · 10b5-1 plan
C—
60.0K sh
Jan 5, 2026Jan 7, 2026
traded Jan 5, 2026
+2dSEC FORM 4

Evidence

0
GC
Gibson ChristopherDirector, Chief Executive Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Derivative conversion · 10b5-1 plan
C—
40.0K sh
Dec 19, 2025Dec 19, 2025
traded Dec 19, 2025
+0dSEC FORM 4

Evidence

0
GC
Gibson ChristopherDirector, Chief Executive Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Derivative conversion · 10b5-1 plan
C—
40.0K sh
Dec 19, 2025Dec 19, 2025
traded Dec 19, 2025
+0dSEC FORM 4

Evidence

9
GC
Gibson ChristopherDirector, Chief Executive Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$180K
40.0K sh
Dec 19, 2025Dec 19, 2025
traded Dec 19, 2025
+0dSEC FORM 4

Evidence

0
GC
Gibson ChristopherDirector, Chief Executive Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Derivative conversion · 10b5-1 plan
C—
60.0K sh
Dec 4, 2025Dec 5, 2025
traded Dec 4, 2025
+1dSEC FORM 4

Evidence

9
GC
Gibson ChristopherDirector, Chief Executive Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$185K
40.0K sh
Dec 4, 2025Dec 5, 2025
traded Dec 4, 2025
+1dSEC FORM 4

Evidence

0
GC
Gibson ChristopherDirector, Chief Executive Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Derivative conversion · 10b5-1 plan
C—
60.0K sh
Dec 4, 2025Dec 5, 2025
traded Dec 4, 2025
+1dSEC FORM 4

Evidence

0
GC
Gibson ChristopherDirector, Chief Executive Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Gift · 10b5-1 plan
G—
20.0K sh
Dec 4, 2025Dec 5, 2025
traded Dec 4, 2025
+1dSEC FORM 4

Evidence

0
GC
Gibson ChristopherDirector, Chief Executive Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Tax withholding · 10b5-1 plan
F$167K
40.4K sh
Nov 17, 2025Nov 19, 2025
traded Nov 17, 2025
+2dSEC FORM 4

Evidence

0
GC
Gibson ChristopherDirector, Chief Executive Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Derivative conversion · 10b5-1 plan
C—
40.0K sh
Nov 19, 2025Nov 19, 2025
traded Nov 19, 2025
+0dSEC FORM 4

Evidence

9
GC
Gibson ChristopherDirector, Chief Executive Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$166K
40.0K sh
Nov 19, 2025Nov 19, 2025
traded Nov 19, 2025
+0dSEC FORM 4

Evidence

0
GC
Gibson ChristopherDirector, Chief Executive Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Derivative conversion · 10b5-1 plan
C—
40.0K sh
Nov 19, 2025Nov 19, 2025
traded Nov 19, 2025
+0dSEC FORM 4

Evidence

0
GC
Gibson ChristopherDirector, Chief Executive Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Derivative conversion · 10b5-1 plan
C—
60.0K sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC FORM 4

Evidence

2
GC
Gibson ChristopherDirector, Chief Executive Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Gift · 10b5-1 plan
G—
20.0K sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC FORM 4

Evidence

8
GC
Gibson ChristopherDirector, Chief Executive Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$208K
40.0K sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC FORM 4

Evidence

3
GC
Gibson ChristopherDirector, Chief Executive Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Derivative conversion · 10b5-1 plan
C—
60.0K sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC FORM 4

Evidence